Samsung Biologics has earned an ‘A+’ rating in the 2026 environmental, social and governance (ESG) evaluation by the Korea Institute of Corporate Governance and Sustainability (KCGS), placing it among the top 1.8% of listed companies assessed. The rating marks an increase from ‘A’ in 2025, continuing a series of strong ESG assessments this year and reflecting the company's sustained progress in responsible business practices and sustainability risk management.
The higher overall rating was driven by the company's environmental performance, which received an ‘A+’ rating, supported by improvements in greenhouse gas emissions and water use intensity. Samsung Biologics also made progress across its social and governance initiatives, further advancing its ESG management framework and transparency through enhanced disclosures.
The latest recognition follows several ESG milestones for Samsung Biologics in 2026. In November, the company achieved a 'Negligible Risk' rating from Morningstar Sustainalytics, the lowest risk category, placing it among the top 0.5% of companies assessed in the global pharmaceutical industry. Samsung Biologics also earned an 'A' rating from MSCI ESG Ratings and received EcoVadis' Platinum Sustainability Rating, awarded to the top 1% of companies assessed globally.
These achievements reflect the company's ongoing efforts to embed responsible practices across its operations, including environmental audits, waste management, workplace safety, ethical business conduct and transparent disclosures.
As Samsung Biologics expands its global operations, the company remains committed to advancing ESG management, proactively addressing sustainability-related risks and maintaining the trust of clients and stakeholders.
Samsung Biologics has earned an ‘A+’ rating in the 2026 environmental, social and governance (ESG) evaluation by the Korea Institute of Corporate Governance and Sustainability (KCGS), placing it among the top 1.8% of listed companies assessed. The rating marks an increase from ‘A’ in 2025, continuing a series of strong ESG assessments this year and reflecting the company's sustained progress in responsible business practices and sustainability risk management.
The higher overall rating was driven by the company's environmental performance, which received an ‘A+’ rating, supported by improvements in greenhouse gas emissions and water use intensity. Samsung Biologics also made progress across its social and governance initiatives, further advancing its ESG management framework and transparency through enhanced disclosures.
The latest recognition follows several ESG milestones for Samsung Biologics in 2026. In November, the company achieved a 'Negligible Risk' rating from Morningstar Sustainalytics, the lowest risk category, placing it among the top 0.5% of companies assessed in the global pharmaceutical industry. Samsung Biologics also earned an 'A' rating from MSCI ESG Ratings and received EcoVadis' Platinum Sustainability Rating, awarded to the top 1% of companies assessed globally.
These achievements reflect the company's ongoing efforts to embed responsible practices across its operations, including environmental audits, waste management, workplace safety, ethical business conduct and transparent disclosures.
As Samsung Biologics expands its global operations, the company remains committed to advancing ESG management, proactively addressing sustainability-related risks and maintaining the trust of clients and stakeholders.
Share article
Related Content